Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.31 |
| ▸ | DHX9 | Q08211 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20151747 | 0.79 | LMNA (0.40) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL20152020 | 0.75 | GSK3B (0.36) | MKNK1MKNK2SMN1; SMN2GRNSORT1 | |
| SCHEMBL20151712 | 0.68 | VNN1 (0.43) | ALDH1A1 | |
| SCHEMBL20151888 | 0.68 | NAMPT (0.33) | ALDH1A1LMNASMN1; SMN2GRNSORT1 | |
| SCHEMBL1576731 | 0.67 | SMN1; SMN2 (0.36) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL12719395 | 0.67 | SMN1; SMN2 (0.36) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL13306640 | 0.67 | BRAF (0.43) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL2726728 | 0.67 | BRAF (0.43) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL30852478 | 0.64 | ALDH1A1 (0.39) | ALDH1A1LMNAMKNK1MKNK2DHX9 | |
| SCHEMBL4562354 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2019-08-22 | — | — | US | disclosed |
| WO-2018087021-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | MERCK PATENT GMBH (DE) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256499-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INHIBITORS OF PFKFB | PFKFB1, PFKFB2, PFKFB4 | ALDH1A1 2858/4885LMNA 3989/4885MKNK1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.